HandyLab gets boost for DNA diagnostic:
This article was originally published in Clinica
Executive Summary
HandyLab has received a $2m grant from the US National Institute of Standards and Technologyto develop a cheap and sensitive device for detecting multiple genetic disease markers. The Ann Arbor, Michigan firm is miniaturising electrochemical detection techniques to create a portable, point of care device. Electrochemical detection reduces costs by eliminating the need for optical techniques, according to HandyLab.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.